Payment overview · 2025
General Payments
$318.39
18 reported records · 8 companies
Healthcare provider profile · identity verified
Dawn C Taylor, MD
Allopathic & Osteopathic Physicians|Family Medicine · SPRINGFIELD, KY · NPI 1023115730
Verified facts
What the public records show
CMS Open Payments records show Dawn C Taylor, MD received $318.39 in general payments during 2025 across 18 reported records.
ABBVIE INC. accounted for 29.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Nurtec Odt, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $95.34 | 29.9% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $63.02 | 19.8% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $50.23 | 15.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.14 | 10.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.76 | 6.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.38 | 6.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.93 | 6.3% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.59 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $318.39 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $79.21 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $79.21 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $50.23 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.73 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 127 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 123 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
93 | 20 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
123 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
127 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 352 | 84 |
| Lisinopril | Lisinopril | 327 | 84 |
| Atorvastatin Calcium | Atorvastatin Calcium | 290 | 77 |
| Omeprazole | Omeprazole | 288 | 74 |
| Gabapentin | Gabapentin | 252 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 239 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 225 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 221 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 215 | 56 |
| Simvastatin | Simvastatin | 202 | 47 |
| Furosemide | Furosemide | 198 | 57 |
| Allopurinol | Allopurinol | 177 | 41 |
| Montelukast Sodium | Montelukast Sodium | 163 | 40 |
| Sertraline Hcl | Sertraline Hcl | 140 | 36 |
| Metformin Hcl | Metformin Hcl | 134 | 34 |
| Potassium Chloride | Potassium Chloride | 130 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 130 | 33 |
| Metformin Hcl Er | Metformin Hcl | 129 | 30 |
| Eliquis | Apixaban | 127 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 34 |
| Ozempic | Semaglutide | 123 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 120 | 44 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 118 | 31 |
| Losartan Potassium | Losartan Potassium | 114 | 34 |
| Tramadol Hcl | Tramadol Hcl | 114 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 109 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 105 | 31 |
| Meloxicam | Meloxicam | 99 | 33 |
| Alendronate Sodium | Alendronate Sodium | 98 | 34 |
| Synthroid | Levothyroxine Sodium | 93 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 91 | 16 |
| Buspirone Hcl | Buspirone Hcl | 87 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 24 |
| Trazodone Hcl | Trazodone Hcl | 85 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 80 | 18 |
| Atenolol | Atenolol | 78 | 20 |
| Lovastatin | Lovastatin | 76 | 17 |
| Ezetimibe | Ezetimibe | 75 | 19 |
| Carvedilol | Carvedilol | 73 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 22 |
| Torsemide | Torsemide | 73 | 24 |
| Clonazepam | Clonazepam | 71 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 19 |
| Clonidine Hcl | Clonidine Hcl | 65 | 17 |
| Benazepril Hcl | Benazepril Hcl | 63 | 14 |
| Fluconazole | Fluconazole | 63 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 19 |
| Glimepiride | Glimepiride | 62 | 15 |
| Spironolactone | Spironolactone | 57 | 14 |
| Methylprednisolone | Methylprednisolone | 56 | 44 |
| Estradiol | Estradiol | 55 | 13 |
| Lorazepam | Lorazepam | 55 | 14 |
| Meclizine Hcl | Meclizine Hcl | 55 | 23 |
| Famotidine | Famotidine | 54 | 15 |
| Levofloxacin | Levofloxacin | 54 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 14 |
| Repatha Sureclick | Evolocumab | 53 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 14 |
| Valsartan | Valsartan | 51 | 15 |
| Bupropion Xl | Bupropion Hcl | 50 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 50 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 16 |
| Azithromycin | Azithromycin | 47 | 41 |
| Cefdinir | Cefdinir | 46 | 40 |
| Cephalexin | Cephalexin | 46 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 18 |
| Celecoxib | Celecoxib | 44 | 12 |
| Trulicity | Dulaglutide | 44 | 12 |
| Donepezil Hcl | Donepezil Hcl | 43 | 12 |
| Finasteride | Finasteride | 43 | suppressed |
| Mirtazapine | Mirtazapine | 41 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | 14 |
| Glipizide | Glipizide | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 14 |
| Promethazine Hcl | Promethazine Hcl | 34 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Vascepa | Icosapent Ethyl | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 13 |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 29 | suppressed |
| Novolog Flexpen | Insulin Aspart | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 20 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Prednisone | Prednisone | 26 | 22 |
| Sucralfate | Sucralfate | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 11 |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Nabumetone | Nabumetone | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 15 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Prolia | Denosumab | 20 | 12 |
| Rybelsus | Semaglutide | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Etodolac | Etodolac | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 13 |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Desvenlafaxine Er | Desvenlafaxine | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $318.39 · 18 records | ABBVIE INC. | AIRSUPRA, BREZTRI, Cologuard Collection Kit, ELIQUIS, EVENITY, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, YUPELRI | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error